Astrada *et al.*

Advancements in Managing Wound Biofilm: A Systematic Review and Meta-Analysis of 1

2 **Randomized Controlled Trials on Topical Modalities**

- Abstract 3
- 4 Running Title: Topical Modalities for Wound Biofilm
- 5 Adam Astrada, DHSc., CNS, RN^{1*}
- 6 Rian Adi Pamungkas, DPH, RN^{1,2}
- Khoirul Rista Abidin, M. Biomed, RN^{3,4} 7
- 8 1. School of Nursing, Faculty of Health Sciences, Esa Unggul University, Indonesia
- 9 2. School of Nursing, University of Michigan, USA
- 3. Department of Medical Laboratory Technology, 'Aisyiyah Polytechnics Pontianak, 10
- Pontianak City, Indonesia 11
- 12 4. Department of Biotechnology, Postgraduate School, Padjadjaran University, Indonesia
- *corresponding author: 13
- Adam Astrada, DHSc., CNS, RN 14
- Assistant Professor 15
- School of Nursing, Faculty of Health Sciences, Esa Unggul University, Indonesia 16
- Jl. Arjuna Utara No.9, Kebon Jeruk, Jakarta, Indonesia 11510 17
- Email: adam.astrada@esaunggul.ac.id 18

19

20

- 21
- 22
- 23
- 24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 25

Astrada et al.

26

Abstract

Significance: Gaining insights into the efficacy of topical wound treatments for biofilm
eradication is pivotal to enhancing wound management strategies. Despite numerous
available agents claiming anti-biofilm properties, the substantiating evidence remains
inconclusive. This study aimed to assess the immediate impact of topical wound treatments
on wound biofilm and healing outcomes in acute and chronic ulcers.

Recent Advances: We comprehensively searched PubMed, ClinicalTrials.gov, and Google
Scholar. Additionally, eligible grey literature was incorporated. English-language randomized
controlled trials, observational, cohort, and case-control studies targeting biofilm prevention,
inhibition, or elimination across diverse wound types were included. Primary outcomes
included biofilm presence and elimination, supplemented by secondary outcomes
encompassing reduced wound size, complete closure, and diminished infection indicators.

38 Bacterial load reduction and biofilm presence were also assessed. Critical Issues: Twenty-eight articles met the inclusion criteria. Various modalities were 39 40 identified, including biofilm-visualization techniques like wound blotting and handheld autofluorescence imaging. A notable high bias risk was observed across all studies. Pooled 41 analysis for the primary outcomes was infeasible due to limited eligible studies and data 42 43 reporting challenges. The primary source of bias is the lack of consensus on objectively evaluating the biofilm. As for the secondary outcomes, the pooled analysis for complete 44 45 wound closure (6 RCTs, yielding n=439) and presence of infection/inflammation (2 RCTs, yielding n=284) showed no significant difference, with log odds ratio (LOD) 0.03 (95% CI: -46

47 1.02 - 1.09; $\tau^2 = 1.09$, SE: 1.10, Q=14.33, p=.014) and LOD -0.95 (95% CI: -3.54 - 1.64; $\tau^2 = 2.32$,

48 Q=2.71, *p*=.10), respectively.

Future Direction: Our findings suggest insufficient evidence to support anti-biofilm claims of topical modalities. Clinicians' skill appears to play a pivotal role in biofilm elimination and wound healing enhancement, with potential optimization through visual-guided techniques like wound blotting and autofluorescence imaging. More rigorous clinical trials are warranted to ascertain the efficacy of these techniques.

54 Keywords: antibiofilm; wound biofilm; topical therapy; acute wound; chronic wound; dressing

Astrada et al.

551. Scope and Significance

- Various products and approaches in the market claim to have antibiofilm effects, eventually 56
- 57 improving wound healing. Yet, the studies regarding this claim are inconclusive. This study
- aimed to investigate the pooled effect of topical wound treatments on wound biofilm and 58
- healing outcomes in acute and chronic ulcers. 59

602. Translational Relevance

- 61 This review found insufficient evidence to conclude that any topical modalities, namely
- 62 dressings, ointments, and wound bed preparation techniques, could reduce wound surface
- biofilm across studies. The problem may be raised from the need for more consensus on the 63
- objective evaluation of biofilm itself. 64

653. Clinical Relevance

- The result further emphasizes the critical role of wound care clinicians' skills in wound biofilm 66
- management instead of the types of products or topical modalities used. 67

684. Background

Rationale 69

- 70 Biofilm has become a growing health concern since it contributes to 80% of human
- infections.¹ Microorganisms living within a biofilm are up to 1,000 times more antibiotic-71
- resistant than their planktonic forms.² Biofilm attached to indwelled devices, such as 72
- implants, can cause early implant removal and surgical site infections. The absence of 73
- 74 vascularization in implants creates a potential dead space that fosters microbial attachment
- and biofilm development. Biofilm-associated costs in wounds and surgery are estimated to 75
- reach several 3.3 billion US dollars in European countries.³ Moreover, a growing health threat 76
- by superbugs and multi-drug-resistant pathogens amplifies the need for therapeutic 77
- modalities to tackle biofilms, especially those associated with wounds. 78
- It is estimated that 78.2% of wounds present biofilms.⁴ Since biofilm is ubiquitous in wounds, 79
- multi-modal approaches have been proposed and developed to combat this situation. More 80
- than 40 agents available on the market in various forms claim to have anti-biofilm effects.⁵ 81

Astrada *et al.*

- Yet, the evidence supporting this claim remains unclear. Therefore, this systematic review 82
- and meta-analysis aimed to provide pooled data on topical wound treatments such as 83
- 84 cleansers, ointment, dressings, and therapeutic modalities and their immediate effects on
- 85 biofilm elimination and wound healing in acute and chronic ulcers.

865. Methods

- The search strategy was based on the research question of "To patients with acute or chronic 87
- ulcers (participants), do the topical wound treatments such as cleansers, ointment, dressings, 88
- and therapeutic modalities (intervention) provide anti-biofilm effects or eliminate biofilms 89
- 90 compared to the standard of care or among the products (comparators)." The review
- 91 protocol is reported according to Preferred Reporting Items for Systematic Reviews and
- 92 Meta-Analyses (PRISMA) 2020 and registered in PROSPERO 2023 (ID: CRD42023407421),
- available from: 93
- 94 https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023407421

5.1 Eligibility Criteria 95

96 We aimed to find, assess and synthesize all randomized controlled trials, observational 97 studies (all types), cohort (longitudinal) studies, or case-control studies containing all types of wounds (e.g., acute and chronic wounds, such as diabetic foot ulcers, venous 98 ulcers, surgical site infections, etc.) or clinical studies and trials (e.g., randomized 99 100 controlled trials, non-controlled interventional studies, observational studies involving human subjects). If they used the following interventions wound dressings, ointments, or 101 techniques purposed to prevent, inhibit, or eliminate wound biofilms. 102

103 If biofilm elimination; absence or reduced biofilm structures as observed microscopically, and reduced wound size was reported, we included it as the primary outcome, while if 104 complete wound closure; healed or unhealed or reduced signs of infection; erythema, 105 edema, warmth, pain, and dysfunction were reported, we included them as the 106 secondary outcomes. We included clinical studies conducted in all wound care settings, 107 including in-patient and ambulatory facilities. Non-clinical studies (e.g., in vitro, product 108 development involving subjects without wounds) were excluded. 109

Astrada et al.

5.2 Participants 110

- 111 Included participants were: all types of wounds (e.g., acute and chronic wounds, such as
- diabetic foot ulcers, venous ulcers, surgical site infections, etc.) or clinical studies and 112
- trials (e.g., randomized controlled trials, non-controlled interventional studies, 113
- observational studies involving human subjects). Participants were excluded if the 114
- articles were published in languages other than English or studies not related to wound 115
- biofilms. 116

5.3 Interventions 117

- Studies were eligible if they evaluated the use of wound dressing or ointment to 118
- prevent, inhibit, or eliminate wound biofilms. 119

5.4 Comparators 120

We included: any topical wound interventions (e.g., topical agents or wound dressings, 121 including normal saline, iodine, honey, etc.) deemed as the standard of care or among 122 the products. 123

5.5 Outcomes 124

- Studies with the following primary outcomes were included: biofilm elimination, absence 125
- 126 or reduced biofilm structures observed microscopically, or reduced wound
- 127 size. Secondary outcomes were: complete wound closure: healed or unhealed, or
- infections or signs of infection: erythema, edema, warmth, pain, and dysfunction. 128

5.6 Setting 129

- Studies were conducted in the following settings: all wound care settings, including in-130
- patient and ambulatory facilities. 131

5.7 Study design 132

- We included: randomized controlled trials, observational studies (all types), cohort 133
- (longitudinal) studies, cohort studies, or case-control studies. Only randomized 134
- controlled trials were included in the meta-analysis. 135

Astrada *et al.*

5.8 Search strategy 136


- We included keywords (Appendix 1) in the search string MeSH or other subject terms, 137
- 138 search filters, and text words. AA, a wound care expert, designed the search. The search
- 139 was created with The Systematic Review Accelerator
- (https://pubmed.ncbi.nlm.nih.gov/32004673/). 140
- Searches were done in PubMed, ClinicalTrials.gov, and Google Scholar with predefined 141
- keywords in MeSH terms. The dates searched were inception to 19th August 2022 (see 142
- Appendix 1). We restricted our initial search to exclude certain publication types. 143
- Conference abstracts, theses, articles in press, books or book chapters, and reviews did 144
- not appear in our search results. Only articles published in English were included. We 145
- 146 manually checked the included studies' reference lists, performed a backward citation
- analysis, and had meta-analysis studies. 147

5.9 Study screening and selection 148

5.9.1 Screening 149

150 Screening by title and abstract was conducted by AA and KRA independently. After identification and abstract screening, full texts were retrieved for the 151 remaining articles. Two authors (AA and RAP) reviewed the full texts against the 152 inclusion criteria. Discrepancies were resolved by consensus. Figure 1 shows the 153 PRISMA flow diagram for the selection process. 154

Astrada et al.



Astrada et al.

Table 1. Operational definitions of the outcomes 175

Outcomes		Operational definition
Primary:	Biofilm elimination (a)	Mean/median amount of biofilm
anti-		eliminated from the whole wound
biofilm		bed, as observed quantitatively and
effects		objectively.
	Presence of biofilm (b)	Absence or reduced biofilm
		structures at least 50%, as observed
		microscopically; dichotomous:
		present or absent
Secondary:	Reduced wound size/score (c)	Mean/median of planar wound size
wound		or score reduction by the end of the
healing		study
and	Complete wound closure (d)	Complete epithelization,
infection		dichotomous: healed or unhealed
	Infection/signs of infection	Any presence of signs of infection:
	(e)	erythema, edema, warmth, pain, and
		dysfunction; dichotomous: present
		or absent
	Bacterial load reduction (f)	Amounts of bacteria eliminated from
		the wound surface

176

177	5.9.3 Risk of Bias Assessment
178	Two review authors independently assessed the risk of bias for each study using
179	the Cochrane Risk of Bias 2 tool.
180	5.10 Data analysis
181	The treatment/intervention effect was measured in Comprehensive Meta-Analysis

v3.7. The treatment/intervention effect was calculated using log odds ratios (LOD) for 182

Astrada et al.

183	dichotomous outcomes. We undertook meta-analyses when at least two studies or
184	comparisons reported the same outcome. We used a random effects model. The unit
185	of analysis was individual patients. We did not contact investigators or study sponsors
186	to provide missing data.
187	We used the τ^2 statistic to measure heterogeneity among the included trials. The
188	publication bias / small studies effect was assessed using a Funnel plot.
189	
189	We did not perform a subgroup analysis. Planned sensitivity analyses were: wounds
190	We did not perform a subgroup analysis. Planned sensitivity analyses were: wounds receiving treatment for at least four weeks.

1916. Results

A total of 1,964 records were identified by the systematic search, including 207 relevant
searches in Google Scholar, grey literature, and articles found via reference tracing. Of those,
1,935 were excluded after the title and abstract screening and assessment of the eligibility
criteria, as shown in Figure 1.


Of 28 articles, there are 13 RCTs (yielding 1,058 subjects), 3 case series, 8 interventional
studies without controls, 3 observational studies, and 1 proof-of-concept interventional
study. These studies include types of wound post-surgical^{6,7}, venous⁸⁻¹¹, diabetic foot ulcers
(DFUs)^{12–15}, leg ulcers^{9,16–18}, pressure ulcers^{19–21}, burns²², and unspecified chronic and acute
ulcers^{10,23,32,24–31}.


Of the RCTs, types of topical treatment sought for its anti-biofilm properties include 4
studies that used wound irrigation solution such as poly-hexamethylene biguanide
(PHMB)^{7,8,33} and sodium hypochlorite¹⁶, 3 studies that used antibiotics^{6,23,24}, 2 studies that
used silver-based products^{9,10}, 4 studies that used gel-type ointments^{22,24} and lodosorb[®]
(cadexomer iodine, Smith and Nephew, USA)^{9,12}, 1 study that used negative pressure wound
therapy with instillation¹⁶, and 2 studies that used the visual tool-guided wound
cleansing^{13,14}. The summary of each eligible article is shown in Table 2.

Astrada et al.

208 6.1 Assessment of the Risk of Bias of the Included Studies

- 209 The risk of bias of all and individual RCTs is shown in Figures 2 and 3, respectively. All of
- the RCTs suggest a high risk (70%) of bias (Figure 2), primarily due to the detection bias
- and randomization process (selection bias) (Figure 3). Studies by Borges E et al. (2018)
- and Romanelli M *et al.* (2010) show a high risk of bias in all of the domains (Figure 3).








Figure 3. Risk of bias of individual RCTs.

215

214

Astrada *et al.*

6.2 Anti-Biofilm Effects of the Treatments 217

As the first primary outcome, the biofilm elimination is reported in one RCT by Astrada 218 (2021)¹³; three interventional studies without controls by Lenselink et al. (2011)²⁷ and 219 Metcalf (2016 & 2020)^{28,29}; and two observational studies by Mori et al. (2019)²¹ and 220 Koyanagi *et al.* (2021)²⁰ (Table 2). The meta-analysis was not feasible since only one 221 study was found for each primary outcome. 222

223 Astrada et al. (2021) conducted a double-blinded randomized controlled trial in Indonesia. Patients with DFUs were treated with standard of care (SOC) along with 224 wound-blotting guided biofilm debridement and antimicrobial dressings. The study 225 demonstrated significant anti-biofilm effects, with the intervention group showing a 226 mean \pm SD percentage of biofilm removed of 74.7% \pm 5.33 at week 1, compared to 227 $53.6\% \pm 5.42$ in the control group (p = 0.01). By week 3, a significant reduction in the 228 DMIST total score was observed in the intervention group (5.55 \pm 0.33) compared to the 229 control group (6.92 \pm 0.33, p < 0.01), indicating improved wound healing outcomes. 230

In the study by Lenselink et al. (2011), the patients were treated with Suprasorb X 231 dressings containing PHMB. The study demonstrated that 63% of the patients showed 232 "good reduction," and 32% showed "moderate reduction" in biofilm presence. 233 Additionally, two studies by Metcalf et al. (2016 & 2020) investigated the effectiveness 234 of AQUACEL[™] Ag⁺ (ConvaTec Ltd. UK), a hydrofiber wound dressing containing 235 ionic silver, metal chelating agent, and surfactant in addition to SOC on stagnant 236 or deteriorating chronic ulcers in 4 weeks of intervention shows. In their year 2020's 237 238 study, they found that the 'unwanted' wound bed tissue, assumed as harboring biofilm, changed from 92% to 40% (52% reduction). While in their 2016's study, they 239 demonstrated a 31% reduction in the wounds showing biofilm presence. 240

241 The observational studies by Mori et al. (2019) and Koyanagi et al. (2021) also highlighted the use of the wound-blotting method to evaluate biofilm elimination. In a 242 cross-sectional and retrospective study conducted in Japan by Mori et al. (2019), two 243 studies evaluated the effectiveness of a biofilm-based wound care system in pressure 244 ulcers. The intervention group showed significant anti-biofilm effects, with a higher 245

Astrada et al.

- proportion of biofilm removal (65.2% vs. 38.9%, p = 0.009) and an increased likelihood of 90-day wound healing (adjusted HR: 4.5, 95% CI: 1.3 - 15.0, p = 0.015) compared to the control group.
- The second primary outcome, biofilm presence, is reported only in one RCT by Borges *et* al. $(2018)^8$ and one interventional studies without control by Lenselink *et al.* $(2011)^{27}$
- 251 (Table 2).
- 252 Borges *et al.* (2018) conducted an RCT in Brazil involving patients with venous leg ulcers.
- 253 The intervention group received treatment with a PHMB cleansing solution, while the
- control group received a 0.9% NaCl solution. However, the study did not provide
- 255 quantitative statistical findings on biofilm presence before and after treatment. Thus, the
- results regarding the effect of the intervention on biofilm presence are inconclusive.
- 257 Lenselink *et al.* (2011)²⁷, Metcalf *et al.* (2016 & 2020)^{28,29}, and Borges *et al.* (2018)⁸
- evaluated the primary outcomes only by surrogate or clinical cues such as the presence
- of necrotic tissue or visible gel-like materials found on wound surface (Table 2). Astrada
- 260 *et al.* (2021), Mori *et al.* (2019)²¹, and Koyanagi *et al.* (2021)²⁰ used the wound-blotting
- 261 method to evaluate the primary outcomes (Table 2).

262 6.3 Wound Healing

- 263 For the secondary outcomes, the reduced wound size/score is reported in 6
- 264 RCTs^{9,10,13,14,24,33}, in 6 case series or non-controlled interventional studies^{11,19,26,27,31,34}, and
- 265 2 observational studies^{18,35}. However, the meta-analysis for this outcome could not be
- performed due to the poor data report³³, and data was ununifiable^{9,10,13,14,24}.
- An RCT conducted by Romanelli et al. (2010) in Italy assessed the efficacy of Prontosan® wound irrigation solution compared to normal saline in treating chronic leg ulcers. After a 4-week, no significant difference in wound size reduction was observed between the groups.
- In a 3-arm RCT conducted by Wolcott *et al.* (2015) in the USA, the effectiveness of
 different treatments on acute and chronic ulcers was evaluated. Arm-1 represented the
 control group, receiving SOC management. Arm-2 received Lipogel (Sanguitec gel, USA)

Astrada *et al.*

containing antibiofilm (hammamelitannin, xylitol, gallium) and antibiotics, and Arm-3 274 received SOC along with Lipogel containing personalized antimicrobial. The study 275 included 15 subjects in each arm, and after four weeks of weekly debridement, Arm-3 276 277 demonstrated the most significant improvement in wound size reduction (72%) compared to Arm-1 (47%) and Arm-2 (62%), with statistical significance. 278 Two multicenter RCTs investigated silver-based products. Miller et al. (2010) conducted a 279 multicenter RCT in Australia to compare the effects of nanocrystalline silver and 280 cadexomer iodine treatments on lower leg ulcers, most of which were venous ulcers. 281 After two weeks of treatment with antimicrobial dressings, the mean wound size 282 reduction was 2.12 \pm 2.94 cm² in the silver group and -0.22 \pm 8.18 cm² in the iodine 283 284 group. In Belgium and the Netherlands, Beele et al. (2010) investigated the efficacy of silver alginate/carboxymethylcellulose dressing compared to non-silver calcium alginate 285 fiber dressing in the venous leg and pressure ulcers. After a 4-week duration, the 286 intervention group showed a wound size reduction of 11.9%, whereas the control group 287

exhibited an increase of 31.7% (p<.05). 288

While in the same category of silver-based products, interventional studies without 289 control by Walker et al. (2015), Metcalf et al. (2016), and Harding et al. (2016) 290 investigated the effectiveness of AQUACEL[™] Ag⁺ (ConvaTec Ltd. UK) in addition to SOC 291 292 on stagnant or deteriorating chronic ulcers in 4 weeks of intervention. They found that the mean wound reduction ranged from 54% to 89%. Additionally, Francesco et al. 293 (2022) investigated the use of cream containing SSD and hyaluronic acid in chronic 294 wounds for four weeks. They found 65% wound size reduction (mean reduction 4.85 295 cm^{2}) in 80% ± 4% of wounds, p<.05. 296

Two visual tool-guided RCTs were conducted by Astrada et al. (2021), and Rahma et al. 297 (2022).¹⁴ Astrada *et al.* (2021)¹³ conducted a double-blinded RCT in Indonesia to evaluate 298 the impact of wound-blotting guided biofilm debridement and antimicrobial dressings 299 300 on DFUs compared to SOC. After a 3-week, there was no significant difference in absolute wound size reduction between the groups. However, the intervention group 301 significantly reduced the DMIST³⁶ total score by week 3 (p<.01), indicating improved 302 wound characteristics. While Rahma et al. (2022) conducted an RCT in the UK to assess, 303 the efficacy of autofluorescence imaging-guided wound treatment using MolecuLight i:X 304

- compared to SOC in DFUs. After 12 weeks, the intervention group exhibited a median 305 percentage wound reduction of 91.3% (IQR=47.3-100%), while the control group had a 306 307 median reduction of 72.8% (IQR=22.3-100%).
- 308 Antibiotic-based use is demonstrated in a within-group control case series conducted by Albaugh et al. (2013)¹⁸. They applied a 1-gram vancomycin-impregnated cellulose 309
- dressing on chronic wounds for three weeks. They showed mean \pm SD = 24.6% \pm 13.59 310
- of wound size reduction in the intervention group, while in the control group, the size 311
- seems to increase by $14.5\% \pm 71.91$ (*p*=.014). 312
- Furthermore, a Chinese Medicine-based product by Liu et al. (2019) is presented in a 313
- non-randomized controlled study on 60 pressure ulcers, 30 each for intervention and 314
- control groups. They investigated the application of paste containing lyophilized Yunnan 315
- 316 Baiyao (YB Group Co. Ltd., China) aqueous extract in addition to debridement and 20 -
- 30 minutes of infrared therapy. After three weeks, they found a significant difference in 317
- wound size reduction in the intervention group mean difference of 4.1 cm2. 318
- While for the complete wound closure, it is reported in 8 RCTs^{6,7,9,10,12,14,23,24}, in 8 case 319 series or non-controlled interventional studies^{11,17,25–28,30,34}, and 1 observational study³². 320 Studies by Kim et al. (2018)²³ and Miller et al. (2010)⁹ were not included in the analysis 321 because of the unreported number of events of the wounds reaching closure. 322
- 323 The six RCTs included in the pooled analysis yielding n=439, including the studies by Malizos et al. (2017)⁶, Malone et al. (2019)¹², Wolcott et al. (2015)²⁴, Beele et al. (2010)¹⁰, 324 Ceviker et al. (2015)⁷, and Rahma et al. (2022)¹⁴. 325
- 326 Two antibiotic-based studies investigated this outcome by Malizos et al. (2017) and
- Wolcott et al. (2015). Malizos et al. (2017) conducted a multi-center RCT across Italy, 327
- France, and Belgium, focusing on surgical site post-osteosynthesis for closed fractures. 328
- The intervention group (n=126) used the coating of osteosynthesis implants with 329
- antibiotic-loaded hydrogel (DAC[®]), while the control group (n=127) received un-coated 330
- osteosynthesis implants. After two weeks, wound closure in the intervention group was 331
- 96.0% (121 of 126), while in the control group was 94.5% (120 of 127), p=.76; no 332
- 333 significant difference was observed between groups. On the other hand, a study by
- Wolcott et al. (2015) found that groups receiving Lipogel in combination with antibiotics 334

Astrada et al.

and antibiofilm showed 80% to 93% of wounds achieved closure, while the control

group only had 53%. However, there was no estimation of statistical difference provided.

337 The silver-based product study by Beele *et al.* (2010) also showed no significant

difference between groups regarding wound closure.

Malone et al. (2019) conducted an RCT in Australia focusing on the effectiveness of a 6-

340 week vs. 2-week treatment with Iodosorb® (cadexomer iodine, Smith and Nephew, USA)

341 on DFUs. The study involved eight subjects in the intervention group and ten in the

342 control group. After 12 weeks, the incidence of DFU complete closure was observed in 2

of 10 subjects (20%) in the intervention group, compared to 5 of 8 subjects (62.5%) in

the control group. However, the difference between the groups was not statisticallysignificant (p=.145).

significant (p=.145).

Ceviker et al. (2015) conducted an open-label RCT focusing on coronary bypass postsurgical wounds in Turkey. The intervention group (n=15) received 0.5% PHMB (Actolind) for irrigation and topical application (soaked gauze), while the control group (n=16) received Ringer Lactate Solution (Neoflex) for irrigation and topical application (soaked gauze). After a 3-week, the complete wound closure was 66.7% (10 of 15) in the intervention group and 43.8% (7 of 16) in the control group, with significant differences between groups.

The visual-guided wound intervention study by Rahma *et al.* (2022) shows that by week 12, wounds receiving the autofluorescence imaging-guided wound treatment had the number of wounds healed 13 of 29 (45%, 95% CI 26–64%), while in the control group 6 of 27 (22.2%, 95% CI 9–42%). There was no statistical significance estimated.

357 Figure 4 shows a forest plot of the pooled random effects of 6 RCTs for this outcome

with a log odds ratio (LOD) of 0.03 (95% CI: -1.02 – 1.09). The between-study


heterogeneity variance was estimated at τ^2 =1.09 (SE: 1.10; Q=14.33, *p*=.014). The funnel plot of this outcome is shown in Figure 5.

361

362

Astrada et al.

Effect of Intervention on Complete Wound Closure



Test of heterogeneity Q= 14.33, df= 5, p=.014, l²= 65.1%, r² = 1.09

364

Figure 4. Forest plot of the effect of intervention on complete wound closure. 365

366




Figure 5. Funnel plot of the included studies for the outcome of complete wound closure. 368

Studies were sparse and asymmetrical which indicates those studies had high risk of bias. 369

medRxiv preprint doi: https://doi.org/10.1101/2023.08.20.23294342; this version posted August 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .


Astrada et al.

371 6.4 Inflammation/Infection

- The presence of inflammation/infection was reported in 4 RCTs^{6,7,10,22} and 1 non-372 controlled interventional study³¹. Of the 4 RCTs, 2 studies (Wattanaploy et al., 2017 & 373 Beele et al., 2010) were not included in the meta-analysis due to reporting zero events of 374 inflammation/infection in both groups, therefore giving no weight in the analysis. The 375 pooled analysis vields n=284 from Malizos et al. $(2017)^6$ and Ceviker et al. $(2015)^7$ 376 studies. 377 The use of coating of osteosynthesis implants with antibiotic-loaded hydrogel (DAC®) in 378 a study by Malizos et al. (2017) showed a significant difference between groups where 379 the incidence of inflammation/infection was 0% (0 of 126) in the intervention group. In 380 contrast, the control group exhibited an incidence of 4.7% (6 of 127). 381 The treatment of PHMB-based products as an irrigation solution and topical application 382
- infection rate on coronary bypass post-surgical wounds, as identified by culture, was

in the study by Ceviker et al. (2015) demonstrated that after a 52-week observation, the

- 385 40% in the intervention group and 37.5% in the control group. However, there was no
- 386 significant difference between the groups (p=0.886).
- 387 The pooled estimate of this outcome for those studies is LOD -0.95 (95% CI: -3.54 –
- 388 1.64), while the between-study heterogeneity variance was estimated at τ^2 =2.32
- 389 (Q=2.71, *p*=.10) (Figure 6).



Effect of Intervention on Infections/Signs of Infection

Random effect model Z= -0.72, p=.47 Test of heterogeneity Q= 2.71, df= 1, p=.10, l^2 = 63.06%, τ^2 = 2.32

390

383

391 Figure 6. Forest plot of the effect of intervention on the presence of infection/signs of

392

inflammation.

Astrada *et al.*

6.5 Bioburden 393

- The effect of bacterial load reduction was reported in 4 RCTs^{8,12,16,23} and 5 case series or 394 non-controlled interventional study^{15,17,25,30,31}. However, the pooled analysis of the RCTs 395 was not feasible due to poor data report (Borges et al., 2018 & Kim et al., 2018)^{8,23} and 396 ununifiable outcomes (Yang *et al.*, 2017 & Malone *et al.*, 2019)^{12,16}. The five case series 397 were conducted by Gupta et al. (2019)²⁵, Patel et al. (2021)³⁷, Malone et al. (2021)¹⁵, 398 Dryden *et al.* (2016)³⁰, and Francesco *et al.* (2022)³¹. 399
- Case series by Gupta et al. (2019)²⁵ and Patel et al. (2021)³⁷ studied the use of topical 400 bacteriophage therapy isolated from different water sources (ponds, rivers, and sewers). 401 Using a convenient sample of 20 and 48 chronic non-healing wounds, respectively, they 402
- showed that after a 2-week post-intervention, all wounds became sterile.^{17,25} 403
- Malone *et al.* (2021)¹⁵ studied the application of surfactant gel Plurogel[®] in addition to 404 405 the standard of care and showed that 7 of 10 wounds had a Log10 reduction in bioburden. 406
- Dryden et al. (2016)³⁰ studied the application of Surgihoney RO[™] (Matoke Holdings Ltd., 407
- UK), a pure honey-derived gel with enhanced reactive oxygen species, on acute and 408 chronic ulcers. After four weeks of application, 98% of the wounds exhibited a bacterial 409 load reduction as evaluated via semiguantitative culture, but no statistical significance 410 estimation was provided. 411
- While Francesco *et al.* $(2022)^{31}$ utilized the topical application of hyaluronic acid in 412 combination with silver sulfadiazine on complicated chronic wounds and showed a 413 significant Log10 bacterial load reduction four weeks after the baseline. 414

4157. Discussion

This systematic review and meta-analysis aimed to elucidate the effectiveness of various 416 interventions in targeting biofilms and their impact on wound healing outcomes in clinical 417 studies. According to our review, the effect of any intervention aimed at biofilm elimination 418 419 and complete biofilm presence eradication could not be clarified due to the lack of clinical trials available. However, we could estimate its pooled effect on the secondary outcomes: 420 complete wound closure and presence of inflammation/infection. Still, we found that all the 421

Astrada et al.

422 products claimed to have anti-biofilm properties showed no significant effect in achieving
423 complete wound closure and reducing inflammation/infection compared to the control
424 treatment.

425 Clinical trials we found involving techniques of visual-guided wound cleansing, including wound-blotting guided debridement and autofluorescence imaging camera; and wound care 426 products, including silver-based products, PHMB dressing and irrigation solution, NPWT with 427 instillation of sodium hypochlorite, cadexomer iodine, and antibiotic-impregnated gels. One 428 interesting approach is using topical bacteriophage cocktail studies by Gupta *et al.* (2019)²⁵ 429 and Patel et al. (2021)³⁷in case series studies where the wound became sterile after the 430 cocktail treatment. Although they did not evaluate the biofilm directly itself, this might 431 432 suggest that the treatment might prevent the development of biofilm in the first place, showing the potential for further exploration in the future. 433

434 The problem with studies included in this review is that there needed to be more consensus on objectively evaluating the biofilm. Studies included in this review still rely on the 435 conventional culture method or surrogate end-point, such as clinical signs and symptoms. 436 Studies by Beele et al. (2010) use clinical signs and symptoms to identify biofilms, such as 437 continuous pain, edema, warmth, moderate to heavy exudate, and the presence of slough at 438 439 least 50% of the wound surface, foul odor, or necrotic plagues. Studies by Yang et al. $(2017)^{16}$, Miller et al. $(2010)^9$, and Wolcott et al. $(2015)^{24}$, were also claiming the evaluation of 440 intervention on the biofilm matrix. However, these studies needed to present data regarding 441 the objective evaluation of the biofilm's presence. Instead, they focused on the colony-442 forming unit count and explored its influence on wound healing. Only studies by Borges et 443 al. (2018)⁸ and Malone et al. (2019 & 2021)^{12,15} reported objective evaluation of biofilm using 444 scanning electron microscopy, DNA sequencing, and real-time guantitative polymerase chain 445 reaction (qPCR). Yet this technique was used only to confirm the biofilm presence at the 446 baseline, making the quantitative evaluation at the end of the intervention not possible. This 447 finding alarms the need of consensus for the objective biofilm evaluation for future studies. 448

Using a visual-guided wound cleansing approach may offer a solution in the clinician's best interest more objectively. Techniques such as wound-blotting and autofluorescence-guided imaging may offer a promising approach for assessing biofilm presence and monitoring the effectiveness of interventions in real-time. The wound-blotting technique could visualize the

Astrada et al.

wound surface biofilm by attaching a piece of nitrocellulose membrane on wounds for 10 453 seconds, then stained by Alcian Blue to highlight parts of the wound that still harbor 454 biofilms. This technique has a sensitivity of 100%, as shown in *in vivo* study.³⁸ An RCT by 455 Astrada et al. (2021) and observational studies by Mori et al. (2019)²¹ and Koyanagi et al. 456 (2021)²⁰ show that wound blotting could help clinicians to determine the effectiveness of 457 wound cleansing in real-time as well as improving wound healing. While in The Fluorescence 458 imaging Assessment and Guidance (FLAAG) study, a multi-center diagnostic accuracy study 459 by Le et al. (2022)³⁹ on 350 patients with chronic wounds, shows that the autofluorescence 460 imaging technique could detect $>10^4$ CFU/g in 82% of biopsied wound tissue which mostly 461 462 missed by direct inspection of the clinical signs and symptoms. The study shows this technique has moderate sensitivity (61,0%) but high specificity (84%).³⁹ A study by Rahma et 463 al. (2022)¹⁴ is the first RCT to evaluate this technique, but it is still a pilot study. Regardless, 464 this technique could change 69% of treatment plans, influenced 85% of wound bed 465 preparation, and improved 90% of patient care by 20 clinicians in those centers.³⁹ 466 Additionally, a study by Wu et al. (2022)³² attempted to compare both techniques, i.e., 467 wound-blotting and autofluorescence imaging, in predicting healing in chronic wounds in 90 468 469 days. They found that wound blotting shows a significantly strong correlation coefficient of Kendall's tau value = 0.563, p<.001 to complete wound healing, while MolecuLight i:X 470 471 Exhibited no significant association (p=.184). This indicates that wound blotting may be more beneficial for wound healing prognosis because the wound blotting detects the actual 472 biofilms. In contrast, the autofluorescence bacterial visualization detects planktonic and 473 biofilm forms but cannot distinguish between the two.³⁸ Future research is needed to focus 474 475 on standardized methods for biofilm assessment and to assess the long-term effects of biofilm elimination on wound healing outcomes considering the clinical implications of 476 biofilm elimination in improving patient well-being. 477

Finally, since we found no sufficient evidence supporting the antibiofilm effects of any 478 available products or topical interventions, the skills of wound care clinicians seem to be the 479 most critical factor in biofilm management. This may include the cleansing technique, 480 locating the highly susceptible wound bed for biofilm development, exudate management, 481 antimicrobial selection, and adherence to the timely dressing change. Visual-guided wound 482 cleansing may open a new therapeutic approach to combat wound surface biofilm. 483

Astrada et al.

484

485 Limitations

486 There is a high risk of bias in almost all clinical trials included in the meta-analysis. The

487 primary source of bias is the lack of consensus on objectively evaluating the biofilm. There is

also the risk of selection bias because studies included in the pooled estimation did not

distinguish types of modalities due to the lack of eligible clinical trials.

490

4918. Conclusion

492 This study indicates that there is currently inadequate evidence to support the claims of any

493 topical treatments having an anti-biofilm effect on the healing of acute and chronic wounds.

494 The skill of treating clinicians offers the main contribution in eliminating biofilm and

improving wound healing which can be optimized via visual-guided wound cleansing such as

496 wound blotting and autofluorescence imaging techniques. More rigorous clinical trial studies

497 are needed to clarify the benefit of those techniques.

498

4999. Take-Home Messages

Insufficient Clinical Backing for Anti-Biofilm Treatments: Despite claims, this analysis
 highlights the scarcity of clinical trials supporting biofilm-targeting interventions in
 wound healing, necessitating more substantial evidence.

- Key Clinician Skill in Biofilm Management: The proficiency of wound care practitioners
 stands pivotal in biofilm control and wound healing, encompassing techniques,
 antimicrobial choices, and dressing adherence.
- Visual-Guided Cleansing Shows Promise: Techniques like wound-blotting and
 autofluorescence imaging offer potential in objectively assessing biofilm presence,
 influencing real-time treatment decisions, and warranting further study for enhanced
 wound healing.

Astrada et al.

51110. Authors' Contributions

- 512 AA contributed to the design of this review. AA and KRA collect all data and screen data. AA
- and RAP contributed to data verification and statistical analysis. AA made all figures and 513
- tables. AA, RAP, and KRA contributed to the article writing. AA and RAP revised the article. All 514
- listed authors checked and agreed to the final article. 515
- 516

51711. Acknowledgement and Funding

518 This research received no specific grant from funding agencies in the public, commercial, or

519 not-for-profit sectors.

520

52112. Author Disclosure and Ghostwriting

The authors declare that no conflict of interest might affect the integrity of this work. While 522

preparing this work, the authors used ChatGPT August 3 Version to improve the readability 523

of the text. After using this tool/service, the authors reviewed and edited the content as 524

needed and take full responsibility for the publication's content. 525

526

52713. About the Authors

528 Adam Astrada, an assistant professor at Esa Unggul University and a national board

member of the Indonesian Wound Enterostomal and Continence Nurses Association, who 529

has received a Gold Prize from the Journal of Wound Care Awards 2023 for his works in 530

Advances in Infections and Biofilm. He has published 4 SCI, including 3 articles in the Journal 531

of Wound Care and 1 article in Enfermeria Clinica. 532

533 Rian Adi Pamungkas, an assistant professor and Head of the School of Nursing at Esa

534 Unggul University. He is also a postdoctoral scholar at the University of Michigan.

Khoirul Rista Abidin is a doctoral student in Biotechnology Study Program, at Padjadjaran 535

University. He is a Lecturer at the Department of Medical Laboratory Technology, Aisyiyah 536

Astrada *et al.*

- Polytechnic Pontianak. He also works as a wound care clinician at Komamura Wound & 537
- Obesity Care Center and Aisyiyah Clinic Pontianak. His research interest is 538
- noninfectious diseases. 539

540

54114. Abbreviations and Acronyms

- CL = confidence interval 542
- = defensive antibacterial coating 543 DAC
- DFUs = diabetic foot ulcers 544
- DMIST = depth, maceration, inflection/inflammation, size, tissue of wound bed, tissue of 545
- wound edge, and tunneling/undermining 546
- = log odds ratio LOD 547
- MeSH = medical subject headings 548
- NaCl = natrium chloride 549
- NPWT = negative pressure wound therapy 550
- PFU = plaque forming unit 551
- PHMB = poly-hexamethylene biguanide 552
- PRISMA= preferred reporting items for systematic reviews and meta-analyses 553
- RCTs = randomized controlled trials 554
- SD = standard deviation 555
- SE = standard error 556
- SOC = standard of care 557
- TBSA = total body surface area 558

55915. References

National Health Institute. Research on Microbial Biofilms. 2002. Available from: 1. 560

Actuals -+ -1

	Astrad	a et al.
561 562		https://grants.nih.gov/grants/guide/pa-files/pa-03-047.html [Last accessed: 9/3/2022].
502		
563	2.	Yan J, Bassler BL. Surviving as a Community: Antibiotic Tolerance and
564		Persistence in Bacterial Biofilms. Cell Host Microbe 2019;26(1):15–21; doi:
565		10.1016/j.chom.2019.06.002.
566	3.	Hrynyshyn A, Simões M, Borges A. Biofilms in Surgical Site Infections: Recent
567		Advances and Novel Prevention and Eradication Strategies. Antibiotics
568		2022;11(1):69; doi: 10.3390/antibiotics11010069.
569	4.	Malone M, Bjarnsholt T, Mcbain AJ, et al. The prevalence of biofilms in chronic
570		wounds: a systematic review and meta-analysis of published data. J Wound
571		Care 2017;26(1):20–25.
572	5.	Schwarzer S, James GA, Goeres D, et al. The efficacy of topical agents used in
573		wounds for managing chronic biofilm infections: A systematic review. J Infect
574		2020;80(3):261–270; doi: 10.1016/j.jinf.2019.12.017.
575	6.	Malizos K, Blauth M, Danita A, et al. Fast-resorbable antibiotic-loaded hydrogel
576		coating to reduce post-surgical infection after internal osteosynthesis: a
577		multicenter randomized controlled trial. J Orthop Traumatol 2017;18(2):159-
578		169; doi: 10.1007/s10195-017-0442-2.
579	7.	Ceviker K, Canikoglu M, Tatlioglu S, et al. Reducing the pathogen burden and
580		promoting healing with polyhexanide in non-healing wounds: A prospective
581		study. J Wound Care 2015;24(12):582–586; doi: 10.12968/jowc.2015.24.12.582.
582	8.	Borges EL, Frison SS, Honorato-Sampaio K, et al. Effect of Polyhexamethylene
583		Biguanide Solution on Bacterial Load and Biofilm in Venous Leg Ulcers. J
584		Wound, Ostomy Cont Nurs 2018;45(5):425–431; doi:

585 10.1097/WON.00000000000455.

Miller CN, Newall N, Kapp SE, et al. A randomized-controlled trial comparing 9. 586

Astrada et al.

587	cadexomer	iodine and	nanocrys	stalline sil	lver on the	healing o	f leg ulcers.

Wound Repair Regen 2010;18(4):359-367; doi: 10.1111/j.1524-588

475X.2010.00603.x. 589

10. Beele H, Meuleneire F, Nahuys M, et al. A prospective randomised open label 590 study to evaluate the potential of a new silver alginate/carboxymethylcellulose 591 antimicrobial wound dressing to promote wound healing. Int Wound J 592 2010;7(4):262–270; doi: 10.1111/j.1742-481X.2010.00669.x. 593

Harding KG, Szczepkowski M, Mikosiński J, et al. Safety and performance 594 11. 595 evaluation of a next-generation antimicrobial dressing in patients with chronic venous leg ulcers. Int Wound J 2016;13(4):442-448; doi: 10.1111/iwj.12450. 596

12. Malone M, Schwarzer S, Radzieta M, et al. Effect on total microbial load and 597 community composition with two vs six-week topical Cadexomer lodine for 598 treating chronic biofilm infections in diabetic foot ulcers. Int Wound J 599 2019;16(6):1477-1486; doi: 10.1111/iwj.13219. 600

Astrada A, Nakagami G, Kashiwabara K, et al. Targeting Biofilms in the 13. 601

602 Management of Diabetic Foot Ulcers through Wound Blotting-Guided

Visualization (ウンドブロッティングによる可視化に基づく バイオフィルムを 603

ターゲットとした糖尿病足潰瘍管理). The University of Tokyo; 2021. 604

14. Rahma S, Woods J, Brown S, et al. The Use of Point-of-Care Bacterial 605

Autofluorescence Imaging in the Management of Diabetic Foot Ulcers: A Pilot 606

Randomized Controlled Trial. Diabetes Care 2022;45(7):1601–1609; doi: 607

10.2337/dc21-2218. 608

15. Malone M, Radzieta M, Schwarzer S, et al. Efficacy of a topical concentrated 609 surfactant gel on microbial communities in non-healing diabetic foot ulcers 610 611 with chronic biofilm infections: A proof-of-concept study. Int Wound J 2021;18(4):457-466; doi: 10.1111/iwj.13546. 612

16. Yang C, Goss SG, Alcantara S, et al. Effect of Negative Pressure Wound Therapy 613

Astrada *et al.*

614		With Instillation on Bioburden in Chronically Infected Wounds. Wounds a
615		Compend Clin Res Pract 2017;29(8):240–246.
616	17.	Patel DR, Bhartiya SK, Kumar R, et al. Use of Customized Bacteriophages in the
617		Treatment of Chronic Nonhealing Wounds: A Prospective Study. Int J Low
618		Extrem Wounds 2021;20(1):37–46; doi: 10.1177/1534734619881076.
619	18.	Albaugh KW, Biely SA, Cavorsi JP. The effect of a cellulose dressing and topical
620		vancomycin on methicillin-resistant Staphylococcus aureus (MRSA) and Gram-
621		positive organisms in chronic wounds: a case series. Ostomy Wound Manage
622		2013;59(5):34–43.
623	19.	Liu J, Cai M, Yan H, et al. Yunnan baiyao reduces hospital-acquired pressure
624		ulcers via suppressing virulence gene expression and biofilm formation of
625		staphylococcus aureus. Int J Med Sci 2019;16(8):1078–1088; doi:
626		10.7150/ijms.33723.
627	20.	Koyanagi H, Kitamura A, Nakagami G, et al. Local wound management factors
628		related to biofilm reduction in the pressure ulcer: A prospective observational
629		study. Japan J Nurs Sci 2021;18(2):1–8; doi: 10.1111/jjns.12394.
630	21.	Mori Y, Nakagami G, Kitamura A, et al. Effectiveness of biofilm-based wound
631		care system on wound healing in chronic wounds. Wound Repair Regen
632		2019;27(5):540–547; doi: 10.1111/wrr.12738.
633	22.	Wattanaploy S, Chinaroonchai K, Namviriyachote N, et al. Randomized
634		controlled trial of polyhexanide/betaine gel versus silver sulfadiazine for
635		partial-thickness burn treatment. Int J Low Extrem Wounds 2017;16(1):45–50;
636		doi: 10.1177/1534734617690949.
637	23.	Kim D, Namen Ii W, Moore J, et al. Clinical Assessment of a Biofilm-disrupting
638		Agent for the Management of Chronic Wounds Compared With Standard of
639		Care: A Therapeutic Approach. Wounds a Compend Clin Res Pract
640		2018;30(5):120–130.

Astrada et al.

641	24.	Wolcott R. Disrupting the biofilm matrix improves wound healing outcomes. J
642		Wound Care 2015;24(8):366–371; doi: 10.12968/jowc.2015.24.8.366.
643	25.	Gupta P, Singh HS, Shukla VK, et al. Bacteriophage Therapy of Chronic
644		Nonhealing Wound: Clinical Study. Int J Low Extrem Wounds 2019;18(2):171–
645		175; doi: 10.1177/1534734619835115.
646	26.	Walker M, Metcalf D, Parsons D, et al. A real-life clinical evaluation of a next-
647		generation antimicrobial dressing on acute and chronic wounds. J Wound Care
648		2015;24(1); doi: 10.12968/jowc.2015.24.1.11.
649	27.	Lenselink E, Andriessen A. A cohort study on the efficacy of a polyhexanide-
650		containing biocellulose dressing in the treatment of biofilms in wounds. J
651		Wound Care 2011;20(11):534–539; doi: 10.12968/jowc.2011.20.11.534.
652	28.	Metcalf DG, Bowler PG. Clinical impact of an anti-biofilm hydrofiber dressing in
653		hard-to-heal wounds previously managed with traditional antimicrobial
654		products and systemic antibiotics. Burn Trauma 2020;8:1–9; doi:
655		10.1093/BURNST/TKAA004.
656	29.	Metcalf D, Parsons D, Bowler P. A next-generation antimicrobial wound
657		dressing: a real-life clinical evaluation in the UK and Ireland. J Wound Care
658		2016;25(3):132–138; doi: 10.12968/jowc.2016.25.3.132.
659	30.	Dryden M, Dickinson A, Brooks J, et al. A multi-centre clinical evaluation of
660		reactive oxygen topical wound gel in 114 wounds. J Wound Care
661		2016;25(3):140–146; doi: 10.12968/jowc.2016.25.3.140.
662	31.	De Francesco F, Riccio M, Jimi S. Contribution of Topical Agents such as
663		Hyaluronic Acid and Silver Sulfadiazine to Wound Healing and Management of
664		Bacterial Biofilm. Medicina (B Aires) 2022;58(6):835; doi:
665		10.3390/medicina58060835.
666	32.	Wu Y, Lin Y, Yang H, et al. Point-of-Care Wound Blotting with Alcian Blue

- 667 Grading versus Fluorescence Imaging for Biofilm Detection and Predicting 90-
- Day Healing Outcomes. Biomedicines 2022;10(5):1200; doi:
- 669 10.3390/biomedicines10051200.
- 33. Romanelli M, Dini V, Barbanera S, et al. Evaluation of the efficacy and
- tolerability of a solution containing propyl betaine and polihexanide for wound
- irrigation. Skin Pharmacol Physiol 2010;23(SUPPL. 1):41–44; doi:
- 673 10.1159/000318266.
- 34. Metcalf D, Parsons D, Bowler P. A next-generation antimicrobial wound
- dressing: a real-life clinical evaluation in the UK and Ireland. J Wound Care
 2016;25(3):132–138; doi: 10.12968/jowc.2016.25.3.132.
- Mori Y, Nakagami G, Kitamura A, et al. Effectiveness of biofilm-based wound
 care system on wound healing in chronic wounds. Wound Repair Regen
 2019;27(5):540–547; doi: 10.1111/wrr.12738.
- 36. Oe M, Yotsu RR, Arisandi D, et al. Validity of DMIST for monitoring healing of
 diabetic foot ulcers. Wound Repair Regen 2020;28(4):539–546; doi:
 10.1111/wrr.12816.
- 37. Serena TE, Jalodi O, Serena L, et al. Evaluation of the combination of a biofilmdisrupting agent and negative pressure wound therapy: A case series. J Wound
 Care 2021;30(1):9–14; doi: 10.12968/jowc.2021.30.1.9.
- Astrada A, Nakagami G, Minematsu T, et al. Concurrent validity of biofilm
 detection by wound blotting on hard-to-heal wounds. J Wound Care
 2021;30(Sup4):S4–S13; doi: 10.12968/jowc.2021.30.Sup4.S4.
- 689 39. Le L, Baer M, Briggs P, et al. Diagnostic Accuracy of Point-of-Care Fluorescence
- Imaging for the Detection of Bacterial Burden in Wounds: Results from the
- 691 350-Patient Fluorescence Imaging Assessment and Guidance Trial. Adv Wound
- 692 Care 2021;10(3):123–136; doi: 10.1089/wound.2020.1272.

Astrada et al.

40. Miller CN, Carville K, Newall N, et al. Assessing bacterial burden in wounds:

comparing clinical observation and wound swabs. Int Wound J 2011;8(1):45–55;
 doi: 10.1111/j.1742-481X.2010.00747.x.

095 doi. 10.1111/j.1742-4017.2010.00747.x.

- 41. Metcalf DG, Bowler PG. Clinical impact of an anti-biofilm Hydrofiber dressing in
- hard-to-heal wounds previously managed with traditional antimicrobial
- 698 products and systemic antibiotics. Burn Trauma 2020;8:1–9; doi:

699 10.1093/burnst/tkaa004.

700

70116. Appendix 1

702 16.1 Search Strategies

- 703 PubMed run 17/8/2022
- 704

(""dressing*""[Text Word] OR ""occlusive dressing*""[MeSH Terms] OR 705 ""biological dressing*""[MeSH Terms] OR ""biological dressing*""[Text Word] OR 706 ""bandage*""[Text Word] OR ""bandage*""[MeSH Terms] OR (""ointment*""[Text 707 Word] OR ""topical ointment*""[Text Word] OR ""anti infective agent*""[MeSH 708 Terms] OR ""topical*""[Text Word] OR ""mupirocin*""[MeSH Terms] OR 709 "oxyguinolin*""[MeSH Terms] OR ""sulfacetamide*""[MeSH Terms] OR ""silver 710 sulfadiazine*""[MeSH Terms] OR ""silver protein*""[MeSH Terms] OR 711 ""proflavine*""[MeSH Terms] OR ""povidone iodine*""[MeSH Terms] OR 712 ""natamycin*""[MeSH Terms] OR ""ointment*""[MeSH Terms] OR 713 ""nitrofurazone*""[MeSH Terms] OR ""miconazole*""[MeSH Terms] OR 714 ""hydroxyquinoline*""[MeSH Terms] OR ""hydrogen peroxide*""[MeSH Terms] 715 OR ""hexylresorcinol*""[MeSH Terms] OR ""ethacridin*""[MeSH Terms] OR 716 ""econazole*""[MeSH Terms] OR ""chlorhexidine*""[MeSH Terms] OR 717 ""cetylpyridin*""[MeSH Terms] OR ""camphor*""[MeSH Terms] OR 718 ""benzethonium*""[MeSH Terms])) AND (""antibiofilm*""[Text Word] OR 719

Astrada et al.

720	""biofilm*""[Text Word] OR ""biofilm*""[MeSH Terms] OR ""extracellular
721	polymeric substance matri*""[MeSH Terms]) AND (""wound*""[Text Word] OR
722	""wounds and injuries""[MeSH Terms] OR ""wound infection""[MeSH Terms] OR
723	""wound healing""[MeSH Terms] OR ""surgical wound infection""[MeSH Terms]
724	OR ""surgical wound""[MeSH Terms] OR ""ulcer*""[Text Word] OR ""foot
725	ulcer*""[MeSH Terms] OR ""skin ulcer*""[MeSH Terms] OR ""leg ulcer*""[MeSH
726	Terms] OR ""injur*""[Text Word] OR ""skin injur*""[Text Word] OR ""skin
727	injur*""[Text Word])

72817. Figure Legends

- 729 Figure 1. PRISMA Flow Diagram.
- 730 Figure 2. Risk of bias of all included RCTs.
- 731 Figure 3. Risk of bias of individual RCTs.
- Figure 4. Forest plot of the effect of intervention on complete wound closure.
- 733 Figure 5. Funnel plot of the included studies for the outcome of complete wound closure.
- 734 Studies were sparse and asymmetrical which indicates those studies had high risk of bias.
- **735** Figure 6. Forest plot of the effect of intervention on the presence of infection/signs of
- 736 inflammation.

Table 2. Summary of included studies

No		Year of		Samples	Samples Wound Treatments			End-points,	
	Author	publication, article type	on, Country(es) (n		(n, I/C) type(s) Intervention Control		duration in weeks	Results	
1	Malizos, K.	2017,	Italy,	126/127	Surgical site	Coating of	Un-coated	(d) in 2 weeks	(d) I= 96.0% (121 of 126), C=
	et al. ⁶	Multicenter	France, and		post-	osteosynthesis	osteosynthesis		94.5% (120 of 127), <i>p</i> =.76, no
		RCT	Belgium		osteosynthes	implants with	implants	(e) in 52 weeks;	significant difference between
					is for closed	antibiotic-loaded			groups
					fractures	hydrogel (DAC®)			
									(e) I= 0% (0 of 126), C= 4.7% (6
									of 127), <i>p</i> =.03
2	Borges, E. <i>et</i>	2018, RCT	Brazil	22/22	Venous leg	PHMB cleansing	0.9% NaCl	(b) and (f) all in	(b) the results of biofilm
	al. ⁸				ulcer	solution	solution	one time pre- and	presence before and after
								post-test	treatment were not reported
									quantitatively

									poor report
3	Kim, D. et	2018,	USA	22/21 at	Chronic	Standard	Standard	(c), (d), (f) in 12	(c) relative wound reduction
	al ²³	crossed-over		initial	recalcitrant	debridement +	debridement +	weeks	from the baseline mean \pm
		RCT		enrolmen	wounds (type	triple-antibiotic,	biofilm-		SDI= 72% ± 8%, C= 53%
				t, then 12	was	maximum-	disrupting		(<i>p</i> <.01)
				from	unspecified)	strength	wound gel		
				control		ointment	(BlastX, Next		(d) I= 52%, C= 17%, (p>.05)
				were		(Neosporin +	Science, FL)		
				crossed		pain relief,			(f) difference between the
				over, and		Johnson &			group was not reported
				final		Johnson, NJ)			
				34/21					
4	Yang, C et	2017, RCT	USA	10/10	Leg or foot	NPWT (VAC Ulta,	NPWT (VAC	(f) in 1 week	(f) I= 43% decrease (P<.05); C=
	al. ¹⁶				ulcers size	KCl, USA) with	Ulta, KCI, USA)		14% increase (<i>p</i> =.46)
					>40 cm ²	instillation by			
						sodium			
						hypochlorite			
						0.125%			

(f) unable to determine due to

5	Wattanaplo	2017, RCT	Thailand	23/23	Partial-	Polyhexanide/bet	Silver	(e) 3 weeks	(e) l= 0, C= 0, no significant
	y, S et al. ²²				thickness	aine (0.1%/0.1%)	sulfadiazine		difference between groups
					burns sized	gel (Prontosan	cream		
					>10% TBSA	Wound Gel X, B			
						Braun, Germany)			
6	Romanelli,	2010, RCT	Italy	20/18	Chronic leg	Prontosan [®]	Normal saline	(c) 4 weeks	(c) no significant difference
	M et al. ³³				ulcers, age	wound irrigation			between groups, and the result
					>8 weeks	solution (B Braun,			is not reported appropriately
					old, size	Germany),			(no figures or tables)
					<100 cm ²	containing			
						polyhexanide			
						and propyl			
						betaine			
7	Malone, M	2019, RCT	Australia	8/10	Diabetic foot	A 6-week	A 2-week	(d) & (f) 12 weeks	(d) I= 2 of 10 (20%), C= 5 of 8
	et al. ¹²				ulcers (DFUs)	treatment with	treatment with		(62.5%), <i>p</i> =.145, no significant
						lodosorb®	lodosorb®		difference between groups
						(cadexomer	(cadexomer		
						iodine, Smith and	iodine, Smith		(f) I = 0.5 Log10 (±0.71) 16s
						Nephew, USA)	and Nephew,		copies/mg; C= 0.35 Log10
							USA)		(± 0.36) (p=.71), no significant
									difference between groups

8	Wolcott, R. ²⁴	2015, 3-arm	USA	15/15/15	Acute and	Arm-2 (Gel only):	Arm-1: standard	(c) & (d) in 4	(c) Arm-1= 47%, Arm-2= 62%,
		RCT			chronic	empiric gel	of care (SOC):	weeks	Arm-3= 72%, <i>p</i> <.05
					ulcers	Lipogel	management of		
						(Sanguitec gel,	host barrier to		(d) Arm-1= 53%, Arm-2= 80%,
						USA) containing	healing, weekly		Arm-3= 93%, <i>p</i> <.05
						antibiofilm	debridement		
						(hammamelitanni			
						n, xylitol, gallium)			
						and antibiotics			
						Arm-3: SOC +			
						Lipogel			
						containing			
						personalized			
						antimicrobial			
9	Miller, CN et	2010 &	Australia	133/133	Lower leg	Nanocrystalline	Cadexomer	(c) & (d) in 1 week	(c) Healing rate in 2-week:
	al. ⁹	2011,			ulcers (73.7%	silver, including:	iodine,	on treatment,	Silver= (Mean \pm SD) 2.12 \pm
	Miller, CN et	respectively;			were venous	Acticoat [®] ,	including:	then followed	2.94, lodine= -0.22 ± 8.18
	al. ⁴⁰ *	multicenter			ulcers)	Acticoat [®]	lodosorb [®]	non-antimicrobial	
		RCT				absorbent,	powder,	dressing for 12	(d) lodine= 63%, Silver= 64%,
						Acticoat 7®	lodosorb®	weeks	<i>p</i> >.05

						(Smith &	ointment (Smith		
						Nephew)	& Nephew)		
10	Beele, H <i>et</i>	2010,	Belgium	18/18	Venous leg	silver alginate/	nonsilver	(c), (d) & (e) in 4	(c) I= 11.9%, C= -31.7%,
	al. ¹⁰	multicenter	and		and pressure	carboxymethylcel	calcium alginate	weeks	<i>p</i> =.017
		RCT	Netherland		ulcers	lulose dressing	fiber dressing		
							(Kaltostat,		(d) I= 3 of 18 (16.67%), C= 1 of
							ConvaTec Ltd,		18 (5.56%)
							UK)		
									(e) I= 0, C= 0; no significant
									difference between groups
11	Ceviker, K <i>et</i>	2015, open-	Turkey	15/16	Coronary	0.5% PHMB	Ringer Lactate	(d) & (e) in 3	(d) I= 10 of 15 (66.7%), C= 7 of
	al.7	label RCT			bypass post-	(Actolind, Abem	Solution	weeks	16 (43.8%), <i>p</i> =.181, no
					surgical	Kimya Ltd. Sti.	(Neoflex,		significant difference between
					wounds	lstan- bul,	Turktıpsan Sag.		groups
						Turkey) for	Tic. A.S. Ankara,		
						irrigation and	Turkey) for		(e) Infection rate, identified by
						topical	irrigation and		culture, I= 40%, C= 37.5%,
						application	topical		<i>p</i> =0.886, no significant
						application (soaked gauze)	topical application		<i>p</i> =0.886, no significant difference between groups

12	Astrada, A <i>et al.</i> ¹³	2021, double- blinded RCT	Indonesia	80/82	DFUs	SOC + wound- blotting guided biofilm debridement + antimicrobial dressings	SOC, including mechanical and/or sharp debridement + wound dressing at the discretion of the wound	(a) & (c) in 3 weeks	(a) Mean \pm SD of the percentage of biofilm removed, at week 1 in I= 74.7% \pm 5.33, C= 53.6% \pm 5.42, p=.01; at week 2, I= 71.6% \pm 6.18 and C= 52.0% \pm 6.32, p=.03
							care nurse		(c) there was no difference in absolute wound size reduction between groups, but there was a significant reduction of DMIST total score by week 3, with final total score $I = 5.55 \pm$ 0.33 and $C = 6.92 \pm 0.33$, $p < .01$
13	Rahma, S et al. ¹⁴	2022, RCT	UK	29/27	DFUs	SOC + autofluorescence imaging-guided wound treatment using MolecuLight i:X (MolecuLight Inc.,	SOC, including sharp, nonsurgical debridement of callus and nonviable tissue; review of off-	(c) & (d) in 12 weeks	(c) By week-12, the median percentage wound reduction was I= 91.3% (IQR= 47.3– 100%) vs C= 72.8% (IQR= 22.3 - 100%)

						Canada) a	loading;		(d) By week 12, wounds healed
						handheld camera	identification		were I= 13 of 29 ulcers (45%,
							and treatment		95% CI 26–64%), C= 6 of 27
							of infection; and		(22.2%, 95% CI 9–42%)
							assessment of		
							perfusion with		
							revascularization		
							when clinically		
							indicated		
14	Gupta, P <i>et</i>	2019, case	India	20	Chronic non-	Topical	-	(d) in 12 weeks	(d) 7 of 20 (35%) wounds
	al. ²⁵	series			healing	application of		and (f) in 2 weeks	showed complete closure
					ulcers	cocktail			
						containing 3-			(f) 20 of 20 (100%) wounds
						bacteriophage (at			became sterile
						a dose of 0.1			
						ml/cm ²			
						concentration 10 ⁹			
						PFU/mL) isolated			
						from different			
						water sources			
						(ponds, rivers,			

						and sewer)			
						against			
						S Staphylococcus			
						aureus,			
						Pseudomonas			
						aeruginosa, and			
						Escherichia coli			
15	Patel, DR et	2021, case	India	48	Full-thickness	Topical	-	(d) in 12 weeks	(d) 39 of 48 (81.25) wounds
	al. ¹⁷	series			non-healing	application of		and (f) in 2 weeks	showed complete closure
					chronic leg	cocktail		(5 to 7	
					or foot ulcers	containing single		applications of	(f) 47 of 48 (97.92%) wounds
						or specific		phage therapy)	became sterile
						bacteriophages			
						(at a dose of			
						500µL/cm²)			
16	Liu, J <i>et al</i> . ¹⁹	2019, non-	China	30/30	Hospital-	Debridement,	Debridement,	(c) in 3 weeks	(c) a significant difference in
		randomized			acquired	followed by 20 –	followed by 20 –		wound size reduction in the
		controlled			pressure	30 minutes of	30 minutes of		intervention group mean
		study			ulcers	infrared therapy,	infrared therapy,		difference of 4.1 cm ² (p < .05)
						and application	and application		
						of paste			

						containing	of Vaseline		
						lyophilized	gauze		
						Yunnan Baiyao			
						(YB Group Co.			
						Ltd., China)			
						aqueous extract			
17	Walker, M	2015, multi-	Germany,	113	Slow, non-	AQUACEL™ Ag+	-	(c) & (d) in 4	(c) 63% achieved at least 75%
	et al. ²⁶	national	Italy, the		healing, or	(ConvaTec Ltd.		weeks	wound size reduction
		multi-center	United		deteriorating	UK) Hydrofiber			
		non-	Kingdom,		chronic and	wound dressing			(d) 19 (17%) were healed
		randomized	and		acute ulcers	containing ionic			completely
		intervention	Portugal.		(venous ulcer	silver, metal			
		al study	Spain,		52%, DFU	chelating agent,			
		without a	Slovakia,		12%)	and surfactant			
		control	Canada,			for up to 4 weeks			
			Czech						
			Republic,						
			Netherland						
			s, Sweden,						
			Denmark,						
			Poland						

18	Lenselink, E & Andriessen, A ²⁷	2011, cohort study without a control	Netherland s	28 (16 complete d the study)	Non-healing infected and/or critically	Suprasorb X + - PHMB (lohmann & rauscher GmbH)	(a), (b), (c), & (d) in 24 weeks	(a) 10 of 16 (63%) had 'good reduction', 5 of 16 (32%) had 'moderate reduction', 1 of 16 (6%) had 'no reduction' of
					colonized			biofilm presence
					ulcers			
								(b) 10 (63%) clinically judged
								had no biofilms
								(c) 61% of ulcers had mean \pm
								SD ulcer size reduction = 9.6 \pm
								14.5 cm ²
								(d) 12 (75%) were completely
								healed
19	Metcalf, DG	2020,	UK	65	Deteriorating	Standard care + -	(a) & (d) in the	(a) 'unwanted' wound bed
	& Bowler,	retrospective		(biofilm-	or stagnant	AQUACEL™ Ag+	mean of 4.2	tissue (necrotic, slough,
	PG ⁴¹	cohort study		associate	(chronic)	Extra (ConvaTec	weeks (range 1 –	biofilm) changed from 92% to
		without a		d	ulcers	Ltd. UK)	11 weeks)	40% (52% reduction)
		control		suspicion		Hydrofiber		
				n= 37)		wound dressing		

						containing ionic		(d) 11 of 65 (17%) had
						silver, metal		complete wound closure
						chelating agent,		
						and surfactant		
20	Metcalf, D;	2016, cohort	UK &	29 ulcers	Stalled or	Standard care + -	(a), (c) & (d) up to	(a) A shift from mainly
	Parsons, D;	study	Ireland	from 28	deteriorating	AQUACEL™ Ag+	4 weeks	sloughy/ suspected biofilm (n=
	& Bowler,	without a		subjects	ulcers	Extra (ConvaTec		22, 76%) to 13 (45%), yielding
	P ²⁹	control				Ltd. UK)		31% biofilm reduction
						hydrofiber		
						wound dressing		(c) 26 of 29 (89%), including
						containing ionic		those healed completely and
						silver, metal		those at least 75% closure
						chelating agent,		
						and surfactant		(d) 10 (34%) healed completely
21	Malone, M	2021, proof-	Australia	10	DFUs	SOC + surfactant -	(f) in 6 weeks	(f) 7 of 10 (70%) showed
	<i>et al</i> . ¹⁵	of-concept				gel Plurogel®		reduction (mean \pm SD) 0.8
		intervention				(Medline		Log10 16S copies ± 0.6; while
		al study				Industries Inc.,		3/10 (30%) showed increase
						USA) + non-		0.6 Log10 16S copies ± 0.8
						adherent		
						absorbent		

						dressing pad		
						(Zetuvit,		
						Hartmann		
						Australia)		
22	Dryden, M	2016, multi-	England	114 ulcers	Acute and	Surgihoney RO™ -	(d) & (f) in 4	(d) 24 of 114 (21%) completely
	et al. ³⁰	center		from 104	chronic	(Matoke	weeks (range 1 –	healed
		intervention		subjects	ulcers	Holdings Ltd.,	19 weeks)	
		al study				UK), pure honey-		(f) 39 of 40 (98%) wounds
		without				derived gel with		showed reduction of bacterial
		control				enhanced		load by semi-quantitative
						reactive oxygen		culture (no numerical bacterial
						species		load data shown)
23	Harding, KG	2016,	42	UK &	Chronic	AQUACEL [™] Ag+ -	(c) & (d) in 8	(c) Mean ± SD wound
	et al. ¹¹	intervention	(clinically	Poland	venous ulcers	(ConvaTec Ltd.,	weeks	reduction was 54.5% ± 42.8%
		al study	infected=			UK) hydrofiber		
		without	10 and			wound dressing		(d) 5 of 41 (12.2%) healed
		control	non-			containing ionic		completely
			clinically			silver, metal		
			infected=			chelating agent,		
			32)			and surfactant		
						for 4 weeks,		

						followed by		
						AQUACEL™		
						(ConvaTec Ltd.,		
						UK) hydrofiber		
						wound dressing		
						for another 4		
						weeks		
24	Francesco,	2022,	80	Italy	Complicated	Gauze with -	(c), (e), & (f) in 4	(c) A significant 65% wound
	FD; Riccio,	intervention			chronic	cream or cream	weeks	size reduction (mean reduction
	M; & Jimi,	al study			wounds	only, containing		4.85 cm ²) in 80% ± 4% of
	S. ³¹	without				hyaluronic acid		wounds, <i>p<.</i> 05
		control				and silver		
						sulfadiazine 1%		(e) 75% wounds showed
						(Fidia		absence of inflammation from
						Farmaceutici,		the baseline
						Abano Terme,		
						Italy)		(f) Median bacterial load
								reduction from the baseline 4.5
								log10 CFU/mL to 3.4 log10
								CFU/mL, <i>p</i> <.05

25	Koyanagi, H	2020, muti-	34	Japan	Pressure	Topical	-	(a) in 1 week	(a) application of iodine
	et al. ²⁰	center			ulcers	ointments:			ointment in 10 of 34 (29.4%)
		observationa				iodine,			shows correlation coefficient
		l study				prostaglandin E1,			with biofilm proportion = -0.42
						silver			(p=.02)
						sulfadiazine; or			
						dressings:			
						hydrocolloid,			
						foam/silicone,			
						gauze.			
26	Mori, Y et	2019, cross-	Study 1:	Japan	Pressure	SOC + biofilm-	SOC, including	Study 1: (a) &	(a) Study 1, the proportion of
	al. ²¹	sectional	88/26		ulcers	based wound	sharp	Study 2: (c) in 90	biofilms removed, I= 65.2%
		(study 1)				care system:	debridement	days	(95% Cl: 41.1 – 78.8%) and C=
		and	Study 2:			using wound	and suitable		38.9% (95% Cl: 12.9 – 68.0%),
		retrospective	16/64			blotting as a	wound dressing		<i>p</i> =.009
		(study 2)				guide for biofilm	at the discretion		
		studies				evaluation +	of the physicians		(c) Study 2, adjusted HR for 90-
						sharp and/or			day wound healing (proportion
						non-contact			healed) in the intervention
						ultrasonic			group was 4.5 (95% Cl: 1.3 –
						debridement			15.0, <i>p</i> =.015)

						(Qoustic Wound Therapy System, Arobella Medical, LLC, Minnetonka,			
						MN, USA) at ultrasonic waves			
						of 35 kHz			
27	Albaugh,	2013, within-	23/23	USA	Chronic	3-week	3-week pre-	(c) in 3 weeks	(c) Mean ± SD change wound
	KW; Biely,	group			lower leg	treatment	treatment		surface area, I= -24.6% ±
	SA; &	control, case			ulcers (15/23,	(prospective):	(retrospective):		13.59; C= +14.5% ± 71.91,
	Cavorsi, JP ¹⁸	series			652% were	SOC + 1-gram	SOC		<i>p</i> =.014
					venous	vancomycin-			
					ulcers)	impregnated			
						cellulose dressing			
28	Wu, YF et	2022,	53	Taiwan	Unhealed	The grading	MolecuLight i:X	(d) in 90-day	(d) The modified alcian blue
	al. ³²	observationa			chronic	system of a	(MolecuLight		wound blotting grading system
		l study,			ulcers (72%	modified alcian	Inc., Canada),		shows a significantly strong
		without			were due to	blue staining	handheld		correlation coefficient of
		control			diabetes and	wound blotting, a	autofluorescenc		Kendall's tau value = 0.563,
					trauma)	biofilm	e imaging		<i>p</i> <.001, to complete wound
							camera		healing. While MolecuLight i:X

visualization

method

exhibited no significant association (p=.184)

*posthoc analysis of the RCT by Miller et al. (2010)

RCT= randomized controlled trial, I: intervention, C: control, DAC: Defensive Antibacterial Coating, PHMB: poly hexamethylene biguanide, DFUs: diabetic foot ulcers; NPWT: negative pressure wound therapy, SOC: standard of care; TBSA: total body surface area, PFU: plaque forming unit

- (a) Biofilm elimination
- (b) Presence of biofilm, dichotomous: present/absent
- (c) Reduced wound size/score
- (d) Complete wound closure
- (e) Infections/signs of infection, dichotomous: present/absent
- (f) Bacterial load reduction